Filing Flows › Insight Molecular Diagnostics (IMDX) › Q1 2026 › vs Q4 2025
Insight Molecular Diagnostics (IMDX) Q1 2026 vs Q4 2025 (quarter over quarter)
Insight Molecular Diagnostics's revenue fell $1.1M (-97%) from $1.1M in Q4 2025 to $32K in Q1 2026.
Insight Molecular Diagnostics, Q1 2026: revenue $32K (-98% year over year), net loss $4.3M, operating cash flow −$7.6M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $32K | $1.1M | −$1.1M | -97% |
| Other income, net | $123K | $480K | −$357K | -74% |
| Net loss | $4.3M | $23.0M | −$18.7M | -81% |
| Costs & expenses | $4.4M | $24.6M | −$20.1M | -82% |
| Operating costs | $4.4M | $24.6M | −$20.1M | -82% |
| Cost of revenue | $17K | $643K | −$626K | -97% |
| Operating expenses | $4.4M | $23.9M | −$19.5M | -81% |
| Operating cash sources | $8.9M | $6.8M | $2.1M | +30% |
| Depreciation & amortization | $631K | $563K | $68K | +12% |
| Share-based compensation | $615K | $721K | −$106K | -15% |
| Cash used in operations | $7.6M | $5.5M | $2.1M | +38% |
| Net loss absorbed | $4.3M | $23.0M | −$18.7M | -81% |
| Working capital & other | $4.6M | −$16.1M | $20.7M | — |
Questions
How much did Insight Molecular Diagnostics's revenue grow quarter over quarter in Q1 2026?
Insight Molecular Diagnostics's revenue fell $1.1M (-97%) from $1.1M in Q4 2025 to $32K in Q1 2026.